Risedronate in Osteopenic Postmenopausal Women (OSMAUSE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00345644 |
Recruitment Status
:
Completed
First Posted
: June 28, 2006
Last Update Posted
: December 7, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The primary objective of this study is to compare risedronate 35 mg and placebo with respect to the percent change at 12 months for distal radius trabecular bone volume (BV/TV) in osteopenic postmenopausal women, as measured by three-dimensional peripheral quantitative computed tomography (3D pQCT).
The secondary objectives are to compare the percent change from Screening/Baseline between the 2 treatment groups for the following measurements:
- Bone mineral density of the lumbar spine, femoral neck, femoral trochanter, and total proximal femur using a dual energy X-ray absorptiometry (DXA) scan at 12 and 24 months;
- 3D pQCT analysis of distal radius and distal tibia bone microarchitecture data at 6, 12, and 24 months; and
-
Bone turnover markers (BTMs) of:
- fasting serum carboxyterminal cross linking telopeptide of type 1 bone collagen (CTX 1);
- serum aminoterminal propeptide of type 1 procollagen (PINP); and
- urine N-telopeptide cross-links (NTX) at 3, 6, 12, and 24 months.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoporosis | Drug: risedronate Drug: risedronate placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 156 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 24 Month, Monocenter Study Comparing Weekly Oral Risedronate 35 mg and Placebo |
Study Start Date : | March 2006 |
Actual Primary Completion Date : | June 2009 |
Actual Study Completion Date : | June 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: 1 |
Drug: risedronate
risedronate sodium 35 mg tablets (once a week dose)
|
Placebo Comparator: 2 |
Drug: risedronate placebo
placebo for risedronate tablets (once a week dose)
|
- Efficacy data : 3-D-pQCT Data—Microarchitectural Parameters (Distal Radius BV/TV Measurements) [ Time Frame: BV/TV percent change from Baseline at distal radius as measured in the non dominant wrist at Month 12 ]
- Tolerance data :collection of AEs, with special interest for upper gastrointestinal (UGI) AEs and clinical fractures [ Time Frame: at all visits ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years to 75 Years (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Osteopenic, postmenopausal women, between 55 and 75 years of age with a body mass index (BMI) < 30 kg/m²
Exclusion Criteria:
- Clinical or radiological evidence of osteoporosis
- Severe renal impairment
- Serum 5-hydroxy vitamin D level < 15 ng/ml
- History of recent primary hyperparathyroidism or recent thyroid disorder
- History of any generalized bone disease
- Current use of glucocorticoids, estrogens, progestins, calcium supplements > 1 g/day, vitamin D supplements > 800 IU/day, parathyroid hormone (PTH), or any bisphosphonate for > 1 month at any time within the past 6 months.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00345644
France | |
Sanofi-Aventis | |
Paris, France |
Study Director: | Marie SEBILLE, Dr | Sanofi |
Responsible Party: | Medical Affairs Study Director, sanofi-aventis |
ClinicalTrials.gov Identifier: | NCT00345644 History of Changes |
Other Study ID Numbers: |
HMR4003B_3507 EudraCT # :2005-005598-30 |
First Posted: | June 28, 2006 Key Record Dates |
Last Update Posted: | December 7, 2009 |
Last Verified: | December 2009 |
Keywords provided by Sanofi:
Postmenopausal |
Additional relevant MeSH terms:
Osteoporosis Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Metabolic Diseases Risedronate Sodium |
Etidronic Acid Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Bone Density Conservation Agents Physiological Effects of Drugs |